Monte Rosa Therapeutics, a biotechnology company focused on developing precision medicines to degrade disease-causing proteins, completed a Series B financing of USD 96 million. The financing will enable Monte Rosa to accelerate the growth of its pipeline, advance development candidates into the clinic and bolster its platform capabilities to rationally design and develop small molecule degraders (also known as molecular glues) that hijack the body’s innate ability to degrade proteins. Through this approach Monte Rosa Therapeutics will eradicate undruggable proteins that cause or drive the progression of genomically defined diseases intractable to standard care, including cancer.
The Series B financing was led by Aisling Capital with participation from founding investor Versant Ventures and existing investor New Enterprise Associates. Additional new investors included HBM Healthcare Investments, Cormorant Asset Management, GV, Amzak Health, Casdin Capital, Sixty Degree Capital and Cambridge Asset Management.
Walder Wyss acted as Swiss legal counsel to Monte Rosa Therapeutics on its Series B financing of USD 96 million. The team included Alexander Gutmans (Partner, Corporate/M&A and Venture Capital – pictured) and Karina Tschon (Associate, Corporate/M&A and Venture Capital). Goodwin Procter acted as lead counsel.